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Abstract
Induction of long-term tolerance to b-cell autoantigens has been investigated both in animal models and in human type 1
diabetes (T1D) in order to prevent the disease. As regards external compounds, the dietary plant protein fraction has been
associated with high penetrance of the disease, whereas gluten-free diets prevent T1D in animal models. Herewith we
investigated whether intranasal (i.n.) administration of gliadin or gluten may arrest the diabetogenic process. I.n.
administration of gliadin to 4-week-old NOD mice significantly reduced the diabetes incidence. Similarly, the insulitis was
lowered. Intranasal gliadin also rescued a fraction of prediabetic 13-week-old NOD mice from progressing to clinical onset of
diabetes compared to OVA-treated controls. Vaccination with i.n. gliadin led to an induction of CD4+Foxp3+ T cells and even
more significant induction of cd T cells in mucosal, but not in non-mucosal lymphoid compartments. This prevention
strategy was characterized by an increased proportion of IL-10 and a decreased proportion of IL-2, IL-4 and IFN-c-positive
CD4+Foxp3+ T cells, and IFN-c-positive cd T cells, preferentially in mucosal lymphoid organs. In conclusion, i.n. vaccination
with gliadin, an environmental antigen with possible etiological influence in T1D, may represent a novel, safer strategy for
prevention or even early cure of T1D.
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Introduction
The incidence of type 1 diabetes mellitus (T1D) has been
rapidly increasing during the past decades [1]. In humans, the
autoimmune process is prolonged as clinical onset of the disease
does not occur until approximately 80% or more b cells are
destroyed [2] leaving a time window of opportunity for
therapeutical or preventive intervention in prediabetic individuals.
In animal models of T1D, mucosal administration of b-cell related
autoantigens is a well-established strategy for disease prevention by
induction of islet-specific T regulatory cells (Tregs) that may
prevent the autoimmune aggression locally by mechanism of
bystander suppression [3]. Several b-cell autoantigens, defined
rather by occurrence of autoantibodies than T cell specific
immunoreactivity exclusive for T1D patients, have been used for
prevention of T1D by mucosal (oral, intranasal) administration.
Mucosal administration of insulin [4,5] or GAD [6], GAD65
peptide [7] as well as proinsulin or insulin peptides [8,9] has led to
prevention of T1D in animal models. Several of the autoantigens
have been used in recent human trials, but at present, there is no
established prevention strategy available for human T1D [10,11].
Studies in both NOD mice and BB rats have documented that
T1D is a diet-influenced disease. Wheat flour is an essential
component of diabetes-permissive, non-purified diets and purified
diets based on hydrolyzed casein, lactalbumin or amino acids
prevented development of diabetes in NOD mice and BB rats [12–
14]. We and others have documented that a non-purified, gluten-
free diet highly prevents development of diabetes in NOD mice
[15,16].
The diabetogenic role of gliadin is also implicated by a more
frequent clinical association of T1D and celiac disease. Although
celiac disease and T1D share similar risk HLA antigens, patients
diagnosed with both celiac disease and T1D usually develop
diabetes first and not vice versa [17]. Patients with celiac disease
have an earlier onset of T1D [18] and there is also one report of
enhanced T reactivity to gluten in newly diagnosed type 1
diabetics [19]. Early introduction of dietary gluten was reported to
increase the risk of developing islet autoantibodies in children [20].
Gluten-free diet also induces changes in the gut microbiota of
NOD mice [21]. These observations suggest an etiological role for
gliadin in T1D.
Using the NOD mouse model, we investigated the effect of
intranasal (i.n.) administration of gluten or gliadin at the age of 4
weeks on development of insulitis and clinical onset of diabetes.
We tested whether i.n. vaccination may rescue animals from
developing diabetes when applied just before clinical onset of
diabetes at the age of 13 weeks. We also investigated whether this
i.n. prevention strategy leads to induction of potentially regulatory
T cells and changes in their cytokine profiles.
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Methods
Ethics statement
All animal experiments were carried out according to the
principles of the EU directive 86/609, NIH publication no. 85–23
(revised 1985), and the national animal experimentation act. The
study was approved by the National Animal Experimentation Board
under the Danish GovernmentMinistry of Food Affairs according to
EU directive 86/609, license number 2007/56121434-C3.
Animals
NOD/BomTac mice were obtained from Taconic Europe A/S,
Ry, Denmark and kept under barrier-protected conditions
according to the FELASA guidelines [22]. The mice had free
access to acidified drinking water and were fed standard Altromin
1324 diet (Altromin, Lage, Germany).
Reagents and antibodies
Crude wheat gluten and ovalbumin (OVA) were obtained from
Sigma (Sigma, St. Louis, MO), while gliadin was from Fluka
(Sigma). Phorbol myristate acetate (PMA) and ionomycin were
purchased from Sigma. The following monoclonal antibodies
(mAbs) as well as isotype controls were purchased from BD
Biosciences (BD Biosciences, Mountain View, CA): Alexa Fluor
488-conjugated rat anti-mouse IL-2 (JES6-5H4, IgG2b), IL-4
(11B11, IgG1), IFN-c (XMG1.2, IgG1), FITC-conjugated rat anti-
mouse IL-10 (JES5-16E3, IgG2b) and CD8 (53-6.7; IgG2a,k),
PerCP-Cy5.5-conjugated hamster anti-mouse CD3 (145-2C11;
IgG1,k), rat anti-mouse CD4 (RM4-5; IgG2a,k), CD8 (53-6.7;
IgG2a,k) and PE-conjugated hamster anti-mouse cd T cell
receptor (GL3; IgG2,k) mAbs. Mouse Treg staining kit
Cat.No. 88–8111, PE-conjugated rat anti-mouse Foxp3 mAb
(FJK-16s; IgG2a,k) and FITC-conjugated rat anti-mouse CD4
mAb (RM4-5; IgG2a,k) were from eBioscience (eBioscience, San
Diego, CA). The anti-mouse CD4 mAb (BD Biosciences) was used
in combination with intracellular cytokine staining using Cytofix/
Cytoperm kit (BD Biosciences), while the anti-mouse CD4 mAb
(from the eBioscience kit no. 88–8111) was used when detecting
Foxp3+CD4+ T cells (with no prior PMA inomycin stimulation) by
using the Treg staining kit 88–8111.
Intranasal immunization and monitoring of diabetes
Non-anesthetized 4-week-old NOD female mice (n=16 per
group) were intranasally (i.n.) given 50 mg of OVA, gliadin, and/or
gluten in a total volume of 10 ml (5 ml per nostril). Gliadin, gluten as
well as OVA were dissolved in acidified (0.2% acetic acid) saline
solution. Animals were immunized 5 times every other day. Five
animals per group at the age of 13 weeks were used in separate
experiments for insulitis scoring. NOD mice kept in our facilities
start to progress to clinical onset of diabetes (.12 mmol) at the age
of 14–15 weeks. Thus, at the age of 13 weeks these NODmice have
most of their islets affected by various stages of the mononuclear
infiltrate, i.e. autoimmune aggression against b-cells. In order to test
whether i.n. gliadin vaccination may prevent diabetes also in
animals with advanced autoimmune reaction against b-cells, i.n.
gliadin was tested in 13-week-old prediabetic NODmice (n= 20 per
group). For diabetes incidence studies, 16 to 20 mice per group were
monitored for 210–240 days. NOD mice were inspected daily for
diabetes and from 10 weeks of age screened weekly for glycemia
with Glucometer FreeStyle mini (Hermedico, Brøndby, Denmark).
Diagnosis of diabetes was based on two consecutive positive blood
glucose readings .12 mmol/l during three days.
Histology and insulitis scoring
Insulitis scoring was performed on hematoxylin & eosin stained
pancreata from non-diabetic NOD females (n = 5) at the age of 13
weeks; the age at which non of the animals progressed to clinical
onset of diabetes in our SPF animal facility, while in control groups
majority of islets were affected by some presence of mononuclear
infiltrate (insulitis grades 1–4). One half of the pancreata was fixed
Figure 1. Intranasal (i.n.) administration of gliadin decreases diabetes incidence in NOD mice. A statistically significant decrease in
diabetes incidence was found in NOD mice treated with gliadin (red square) compared to OVA (blue circle), *p = 0.001 or PBS (black triangle),
#p= 0.008 controls, whereas no diabetes-protective effect was found in gluten-treated (green square) group. The gliadin-treated group displayed
decreased diabetes incidence (1p=0.029) also compared to gluten-treated (closed circle) NOD mice. Results are representative of three or two
(gluten) independent experiments.
doi:10.1371/journal.pone.0094530.g001
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in 4% formaldehyde, embedded in paraffin, cut in 5 mm sections
and stained with hematoxylin & eosin for insulitis scoring. The
grades for insulitis scoring were as follows: 0, normal islet; 1, intact
islet with few scattered mononuclear cells in the surroundings; 2,
peri-insulitis; 3, insulitis (,50% of the islet infiltrated); 4, severe
insulitis (.50% of the islet infiltrated). A minimum of 25 islets
were scored for each mouse and this experiment was carried out
independently of diabetes incidence studies. Data are expressed as
average percentage of islets affected by the 5 (0–4) insulitis grades
(percent of islets) calculated from 5 animals per group.
Flow cytometry
Single cell suspensions of 8-week-old, normoglycaemic animals
were prepared from the following mucosal lymphoid tissues: the
nasal-associated lymphoid tissue (NALT), pancreatic lymph nodes
(PLN), and mesenteric lymph nodes (MLN). Spleens (S) and
systemic (inguinal) lymph nodes (ILN) were used as non-mucosal
controls. For detection of Foxp3+CD4+ Tregs, intracellular
staining for Foxp3 was carried out using the Treg staining kit
88–8111 (eBioscience) following the manufacturer procedure.
When detecting intracellular cytokines, isolated cells were stimu-
lated in vitro with a mixture of PMA (25 ng/ml) and ionomycin
(1 mg/ml) in RPMI-1640, 10% FCS for 4 hours at 37uC, 5% CO2
in the presence of Golgi Stop (Cytofix/Cytoperm kit, BD
Biosciences) before subsequent staining for selected surface and
intracellular markers. Titration experiments were performed to
determine optimal lengths (1–6 hours) and concentrations of
PMA/ionomycin stimulation. Unstimulated cells cultured in the
presence of Golgi Stop were used as controls. For surface staining,
cells were incubated in FACS buffer with relevant mAbs for 30
minutes on ice. Fc block (CD16/CD32) was from BD Biosciences.
For intracellular staining of cytokines, live cells were first stained
for surface markers, then fixed/permeabilized with the Cytofix/
Cytoperm kit following the manufacturer procedure. No differ-
ence in the staining was observed when comparing sequential
versus one step procedure. Thus, anti-Foxp3 and an anti-cytokine
mAbs were added in a single incubation step. Cells from OVA-
and gliadin-treated mice were prepared, stained and measured on
the same day. Cells were then analyzed by flow cytometry using a
FACSscan (BD Biosciences), and data were analyzed by use of
CellQuest (BD Biosciences), WinMDI 2.8 and/or FlowJo
(TreeStar) software. Only very few cytokine-positive cells were
detected in unstimulated controls. Isotype control antibodies were
used to determine the amount of non-specific binding, and
propidium iodide was used to localize and assess proportion of
dead cells prior their fixation/permeabilization.
Statistics
The cumulative diabetes incidence was assessed using the
Kaplan-Meier estimation and contingency tables. Log-rank test
and Chi-squre test were used for comparisons between groups.
Other results are expressed as mean 6SEM, and the level of
significance (p,0.05) was assayed by two-sample analysis (unpaired
t-test) or ANOVA followed by the Bonferroni multiple comparison
test (comparison of multiple groups in insulitis scoring).
Results
I.n. administration of gliadin leads to reduced diabetes
incidence in NOD mice
As shown in Fig. 1., five intranasal administrations of gliadin
(50 mg) to 4-week-old NOD females significantly decreased the
diabetes incidence to 56% in comparison to mice treated with
OVA with a diabetes incidence of 100%, p= 0.001 (by log-rank
test) and to PBS-treated controls (94%, p= 0.008). There were no
substantial differences in the development of diabetes incidence
between the phosphate-buffered saline (PBS) and OVA-treated
control groups. I.n. administered wheat gluten consisting mainly of
glutenins and gliadins and thus comprising the gliadin fraction,
although in smaller amounts, had no effect on the diabetes
incidence (81% at 210 days) compared to PBS and OVA controls
(Fig. 1). The difference in diabetes incidence between the gluten
(81%) and gliadin (56%) treated groups was again statistically
significant at p = 0.029 (by log-rank test). Additionally, we
investigated a more intense i.n. application scheme in which the
five intranasal application of gliadin (50 mg) every other day were
first applied to 4-week-old NOD mice and then repeated 2 times
more, each time with a 10-day break interval. However, this high-
frequency scheme of i.n. gliadin resulted in no significant diabetes
prevention in NOD mice (data not shown) and is in accord with
data from a mathematical model of NOD mice published by
Fousteri G. et al. [23] in which high-frequency i.n. immunizations
also failed in simulated disease protection. We also tested whether
i.n. administration of gliadin leads to induction of tolerance but
found no differences among the gliadin, OVA (and PBS) i.n.
treated groups of mice in serum anti-gliadin IgG after s.c.
immunization with gliadin in CFA as well as in cytokine recall
responses (IFN-c IL-5 and IL-10) after in vitro restimulation of
MLNs suspensions (data not shown).
Reduction of insulitis by i.n. administration of gliadin
Insulitis scores from 13-week-old NOD female mice are
overviewed in Fig. 2. Gliadin-treated NOD females (insulitis score
Figure 2. Intranasal administration of gliadin but not gluten
prevented development of insulitis in NODmice. (A) Insulitis was
assessed by histological examination at 13 weeks of age before clinical
onset of diabetes. The five grades (0–4) for insulitis scoring are
described in the Research Design and Methods. Five mice per group
and a minimum of 25 islets/mouse were scored and this experiment
was carried out independently of diabetes incidence studies. (B)
Photomicrographs of H&E stained histological specimens documenting
an example islet of grade level 0 (a), 4 (b) and 3 (c) used for insulitis
scoring. Example photomicrographs of grade level 0 (a), 4 (b) and 3 (c)
are from 13-week-old NOD mice treated with gliadin, OVA, and gluten,
respectively. Scale bars: 100 mm.
doi:10.1371/journal.pone.0094530.g002
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1.4460.11) revealed statistically significant, less destructive insu-
litis compared to OVA (2.4460.11, p,0.001) and PBS
(2.3660.10; p,0.001), but also to gluten (2.5560.09; p,0.05)
treated groups (Fig 2A). There were no significant differences
among the gluten-treated and control (PBS, OVA) groups. Thus,
in accord with the diabetes incidence data, insulitis scoring
indicated a significant beneficial effect of gliadin on islet
preservation. Animals used for insulitis scoring were from time
different i.n. experiment. Fig. 2B illustrates examples of three
different grades used for insulitis scoring.
I.n. gliadin reduces diabetes incidence even in 13-week-
old NOD mice just before the clinical onset of diabetes
Five i.n. administrations of gliadin to prediabetic NOD females
at the age of 13 weeks decreased the diabetes incidence compared
to OVA-treated controls (p = 0.017, contingency tables and Chi-
squre test, Fig. 3). Thus, i.n. administration of gliadin could rescue
a small, but statistically still significant, proportion of the animals
from progressing towards manifestation of the disease with
glycemia values still below 12 mmol, in spite of a high degree of
autoimmune infiltrate and damage present at this age in endocrine
pancreata of NOD mice.
I.n. administration of gliadin increases number
CD4+Foxp3+ T cells in mucosal but not in non-mucosal
lymphoid organs
I.n. administration of gliadin to NOD mice led to increased
number of CD4+Foxp3+ T cells at 8 weeks of age. Increased
proportion of these cells was gliadin-specific in comparison with the
i.n. administered control protein - OVA at the site of the antigen
administration - in the NALT and in the mucosal draining lymph
nodes of the pancreas – PLN, and MLN. Thus, an increase of
CD3+CD4+Foxp3+ cells was found in NALT (p=0.013), MLN
(p=0.014) and PLN (p=0.019) after i.n. gliadin vaccination (Fig. 4A).
These data are significant also when expressed as proportion of CD4+
helper T cells (NALT, p=0.019; MLN, p=0.011; PLN, p=0.049),
(Fig. 4B and C). Interestingly, the i.n. gliadin-mediated increase of
Foxp3+ T cells was not found in other non-mucosal lymphoid organs
such as spleen and control systemic ILN (Fig. 4).
I.n. administration of gliadin leads to increased numbers
of cd T cells in mucosal but not in non-mucosal lymphoid
organs
I.n. administration of gliadin to NOD mice led to a mucosal-
specific accumulation of cd T (CD3+) cells at the age of 8 weeks.
Thus i.n. gliadin led to a substantially increased frequency of cd T
cells in NALT (p= 0.004), MLN (p= 0.004), and PLN (p= 0.001),
but not in non-mucosal lymphoid organs such as spleen and ILN
compared to OVA-treated controls (Fig. 5A and B). The increased
frequency of cd T (CD3-gated) cells was found both within the
CD8- cd T cell subset (NALT, p= 0.027; MLN, p= 0.013; PLN,
p= 0.001) as well as in cd T cells expressing CD8 marker (NALT,
p= 0.002; MLN, p= 0.008; PLN, p= 0.007) (Fig. 5C and D). In
gliadin-treated NOD mice, there was a shift towards increased
proportion of CD8+ cd T (CD3+) cells at the site of the
immunization - the NALT and MLN. On the other hand, a
relatively higher proportion of CD8- cd T (CD3+) cells was detected
in the draining lymph nodes of pancreas - the PLN (Fig. 5C and D).
Cytokine profiles of CD4+Foxp3+ and cd T cells after i.n.
administration of gliadin in mucosal and non-mucosal
lymphoid organs
I.n. administration of gliadin is associated with increased
amount of IL-10 and decreased amount of IL-2, IL-4 and IFN-c
in CD4+Foxp3+ T cells, preferentially in mucosal lymphoid organs
in 8-week-old NOD mice. Following PMA/ionomycin stimulation
Figure 3. Intranasal administration of gliadin in prediabetic NODmice with advanced insulitis decreases diabetes incidence. Groups
(n = 20) of 13-week-old NOD female mice received five i.n. administrations (every other day). A statistically significant decrease in diabetes incidence
was found at the age of 240 days in prediabetic NOD mice treated with gliadin (closed circle) compared to OVA control (opened square); *p = 0.017.
While control OVA-treated mice display 100% diabetes incidence, only 75% gliadin-treated littermates progressed to the disease at 240 days.
doi:10.1371/journal.pone.0094530.g003
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in vitro, an increased number of IL-10 positive CD4+Foxp3+ cells
was found both in MLN (p,0.01) and PLN (p,0.05), but also in
non-mucosal ILN (p,0.05) of the gliadin-treated NOD mice at
the age of 8 weeks (Fig. 6B and C). On the other hand,
CD4+Foxp3+ T cells from the gliadin-treated group displayed
lower potential to produce IL-4 (MLN, p,0.001; NALT, p,0.05),
IL-2 (ILN, p,0.01; NALT, p,0.05), and IFN-c (MLN, p,0.05;
PLN, p,0.05; NALT, p,0.05) (Fig. 6A, D and E). Only very few
cytokine-positive cells were detected in unstimulated controls
(example data in Fig. 6F). The most consistent difference was
observed in the IFN-c production of CD4+Foxp3+ T cells that was
significantly reduced in all the mucosal lymphoid organs studied,
including the pancreatic draining PLNs (Fig. 6E).
Within the CD4+Foxp32 subset of T cells, only a small
percentage of cells was positive for IL-4, IL-10 and IFN-c.
Substantially more CD4+Foxp32 T helper cells were positive for
IL-2 and a significantly increased number of IL-2 producing
CD4+Foxp32 T helper cells was detected in all organs studied
(Fig. 6D). IL-10 positive CD4+Foxp32 T cells were also more
frequent in all studied organs except for NALT in the gliadin-
treated group (Fig. 6B and C). A decreased amount of IL-4 was
found in all mucosal (MLN, p,0.05; PLN, p,0.01; NALT, p,
0.05) lymphoid tissues of gliadin-treated mice, whereas IFN-c was
increased in spleen (p,0.01) and MLN (p,0.05), (Fig. 6A and E).
Almost no IL-2 and IL-4 positive cd T cells were detected after
in vitro restimulation with PMA and ionomycin (data not shown)
regardless of the i.n. treatment. Although i.n. gliadin led to
significantly increased induction of cd T (CD3+) cells in all studied
mucosal lymphoid organs (Fig. 5), cd T cells displayed no
substantial differences in positivity for IL-10 as regards the i.n.
treatment with gliadin and OVA (Fig. 7C). Diabetes-preventive
i.n. administration of gliadin was associated with a decreased
number of IFN-c positive cd T cells in MLN (p,0.05) and a
similar tendency was observed in their PLN (Fig. 7A and B).
Discussion
We have shown that five intranasal administrations of 50 mg
gliadin in 4-week-old NOD mice significantly reduce penetrance
of diabetes as well as the level of insulitis. This gliadin treatment
Figure 4. Induction of CD4+Foxp3+ T cells by intranasal administration of gliadin. (A) Proportion of CD4+Foxp3+ cells within T (CD3-gated)
cells in mucosal (NALT, MLN, PLN) and non-mucosal compartments (Spleen, ILN) after i.n. gliadin (white bars) or OVA (black bars) vaccination in 8-
week-old NOD female mice. (B) Proportion of CD4+Foxp3+ cells expressed as percentage of CD3+CD4+ T cell subset; lymphoid organs and bars as ad
A. (C) Example FACS analysis of CD4+Foxp3+ T cells in MLN, PLN and NALT of gliadin and OVA-treated NOD mice. Cells were gated according to the
CD3 parameter and Foxp3 expression analyzed within the CD4-positive cells (histograms). Individual measurements were performed on cells pooled
from 2-3 experimental animals. Data are expressed as mean values 6SEM and represent an example of two independent experiments. *p,0.05.
doi:10.1371/journal.pone.0094530.g004
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was accompanied by an increase of CD4+Foxp3 T cells and much
higher increase of cd T cells in mucosal lymphoid compartments.
Moreover, i.n. gliadin can even rescue a small fraction of
prediabetic 13-week-old NOD mice (with a high degree of
insulitis) from progressing to clinical onset of the disease. Thus,
in this study an environmental antigen, closely related to the
development of T1D, has been successfully applied in the disease
prevention.
Prevention of T1D in NOD mice by i.n. gliadin was associated
with an increased proportion of CD4+Foxp3+ and even more
significant increase of cd T cells specifically in the mucosal
lymphoid compartments, but not in systemic lymphoid organs
such as spleen and ILN (Fig. 4 and 5). Thus, these cells were found
at the site of the i.n. application (NALT) at the draining lymph
nodes (PLN) of the target organ, the pancreas, as well as in gut
draining mucosal lymph nodes, MLN. This distribution pattern
supports the concept of ‘‘common mucosal system’’ [24]. The
increase of cd T cells and Foxp3+ Tregs specifically in the
pancreatic-draining PLN and also in MLN, in which priming of
diabetogenic cells has been reported [25], points to possible
mechanism of bystander suppression [26]. The increased propor-
tion of IL-10 in Foxp3+ Tregs, preferentially within the mucosal
compartment, and a decrease of IFN-c in both Foxp3+ Tregs and
cd T cells after i.n. gliadin (Fig. 6 and 7) are in accord with the
previously reported role of IL-10 cytokine produced by disease
protective Tregs [5,26,27].
It has been suggested that a deficiency of Tregs could be
associated with T1D development, and defective suppressor
function in CD4+CD25+ T cells was reported in T1D patients
[28,29]. Although we found increased proportions of both Foxp3+
and cd T cells after i.n. gliadin, the effect on cd T cells seems to be
substantially larger. cd T cells are not generally considered as a
typical Treg subset, however there are several lines of evidence for
their involvement and even regulatory role in T1D [5,30–32]. We
have documented that NOD mice display an increased proportion
of cd T cells at onset of diabetes [33]. cd T cells specific for insulin
peptide B:9–23 were also reported in NOD mice [34]. On the
other hand, cd T cells play an important role in induction and
maintenance of oral tolerance [35]. It has been shown that in the
neonatal thymectomy NOD model of T1D, gut intraepithelial
CD8+cd T cells can prevent development of diabetes, and proper
development of intraepithelial cd T cells is required for induction
Figure 5. Effect of i.n. administration of gliadin on frequency of cd T cells. (A) Proportion of cd T cells within T (CD3-gated) cells in mucosal
(NALT, MLN, PLN) and non-mucosal compartments (Spleen, ILN) after i.n. gliadin (white bars) or OVA (black bars) administration in 8-week-old NOD
female mice. Panels C and D show further analysis of the cd T cells according to their CD8 expression; lymphoid organs and bars as ad A. (C)
Proportion of CD8- cd T cells expressed as percentage of CD3+ T cells. (D) Proportion of CD8+ cd T cells expressed as percentage of CD3+ T cells. (B)
Example FACS analysis of cd T cells (CD3-gated) in MLN and PLN of NOD mice treated i.n. with gliadin or OVA. Individual measurements were
performed on cells pooled from 2–3 experimental animals. Data are expressed as mean values 6SEM and represent an example of two independent
experiments. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0094530.g005
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of regulatory CD4+CD25+ T cells by oral insulin [32]. Interest-
ingly, intranasal aerosol application of the whole insulin molecule
in NOD mice led to induction of CD8+cd T cells capable of
preventing development of diabetes in an adoptive cotransfer
model [5]. This study corresponds with our data documenting that
i.n. administration of another whole-molecule antigen - gliadin -
also led to preferential induction of cd T cells.
Several of the animal-tested T1D autoantigens proceeded to
human trials e.g. oral or intranasal insulin administration in
humans at risk of type 1 diabetes (DPT-1, INIT). While some
human trials are in progress, others such as the Diabetes
Prevention Trial-1 (DPT-1) with oral or s.c. and i.v. insulin or
s.c. GAD65/alum failed to show a protective effect [10,36–38].
Also in other autoimmune diseases, human trials with oral
autoantigens have not led to satisfactory outcomes - (reviewed in
[39].
Nevertheless, there are a few aspects that may question the use
of b-cell autoantigens in mucosal prevention of autoimmune
diseases, in particular T1D. Firstly, type 1 diabetes is an
autoimmune disease for which the Witebsky and Rose’s original
autoimmune criterion of disease-induction with a specific autoan-
tigen has never been met [40]. In fact, immunizations with neither
b-cell autoantigens nor pancreatic extract together with adjuvants
were able to induce T1D, reviewed in [41]. Secondly, since
mucosally administered antigens can induce both tolerance as well
as immunity, any use of ‘‘self’’ antigens requires extensive testing
and cautions for induction of autoimmunity [9,42,43]. Thus,
vaccinations with b-cell related autoantigens have not so far
proven valuable for humans, although combination therapy with
Figure 6. Cytokine profiles of CD4+Foxp3+ and CD4+Foxp3- cells after i.n. administration of gliadin. Frequency of cytokine-positive cells
in mucosal (NALT, MLN, PLN) and non-mucosal compartments (Spleen, ILN) after 4 hours unspecific in vitro restimulation with PMA/ionomycin is
shown in panel A (IL-4), B (IL-10), D (IL-2) and E (IFN-c). Left panels display cytokines expression in CD4+Foxp3+ and right panels in CD4+Foxp32 cells.
(C) Example FACS analysis of IL-10 expression within CD4+Foxp3+ (Spleen, ILN, MLN, PLN and NALT) and IL-2 positive cells within CD4+Foxp32 subset
(MLN) of 8-week-old NOD mice vaccinated i.n. with gliadin or OVA at 4 weeks of age. (F) Example of IL-10 and IL-2 positive cells in unstimulated
controls (cell subsets and organs as at C). Individual measurements were performed on cells pooled from 2–3 experimental animals at age of 8 weeks.
Data are expressed as mean values 6SEM, i.n. gliadin (white bars), i.n. OVA (black bars). *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0094530.g006
Figure 7. Expression of IL-10 and IFN-c in cd T cells after i.n. administration of gliadin. Proportion of IFN-c (panel A) and IL-10 (panel C)
positive cd T cells within mucosal (NALT, MLN, PLN) and non-mucosal compartments (Spleen, ILN) after i.n. gliadin (white bars) or OVA (black bars)
administration in 8-week-old NOD female mice. (B) Example FACS analysis of IFN-c expression within cd T cells in MLN and PLN of NOD mice treated
i.n. with gliadin or OVA after 4 hours in vitro restimulation with PMA/ionomycin. (C) Example of IFN-c positivity within cd T cells of unstimulated
controls (PLN) from gliadin-treated NOD mice. Individual measurements were performed on cells pooled from 2–3 experimental animals. Data are
expressed as mean values 6SEM, *p,0.05.
doi:10.1371/journal.pone.0094530.g007
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immunosuppressive anti-CD3 mAb seems to be promising
[11,26].
In contrast to gliadin, i.n. administration of gluten did not lead
to prevention of diabetes in NOD mice. This could be due to a
lower dose of gliadin present in the gluten fraction. We
hypothesize, it might also be a matter of availability - e.g.
transports on mucosal surfaces and presentation by DCs, as
glutenins are formed by much higher molecular weight polypep-
tide chains that tend to form a molecular net, thus may limit
availability of various gliadins within the gluten fraction. The effect
of gliadin on immune responses is not fully understood. Prevention
of T1D by i.n. gliadin did not induced specific tolerance to gliadin.
This might be due to the fact that the 4- or even 13-week-old
NOD mice fed standard gluten-containing diet have already well-
established oral tolerance to gliadin, since a very short period of
oral antigen exposure is needed for induction of oral tolerance
[44]. Gliadin induces activation of innate immune mechanisms
and maturation of dendritic cells [45]. While gliadin-induced
inflammatory cytokine production was described as MyD88-
dependent, TLR2 and TLR4 were reported as not involved in the
gliadin-induced signaling pathway [46,47]. Furthermore, gliadin
derived peptides may trigger T cell specific responses but also
stimulate innate immunity response [48]. Gluten-free diets but also
gluten content in diets influence diabetes incidence in animal
models [15,16,49]. The etiological role of gliadin in T1D is
supported by the study by Galipeau HJ et al. [50] documenting
that while sensitization with gliadin induces only moderate
enteropathy in humanized NOD-DQ8 mice, when combined
with partial antibody depletion of Foxp3 Tregs it led to
development of insulitis. The induction of mucosal cd T cells by
i.n. gliadin corresponds with our recent reciprocal finding: we
found decreased proportions of cd T cells in mucosal and non-
mucosal compartments of BALB/c mice fed standard compared to
a gluten-free diet [51].
The use of an external environmental substance, gliadin, in this
study is novel and may have clinical implications. In addition,
gliadin represents one of the most common food antigens in
western countries, thus its safety in human application may be
easier to test compared to b-cell related autoantigens [9,42,43].
In conclusion, our data show that i.n. mucosal application of
gliadin is capable of significant prevention of diabetes and
development of insulitis in NOD mice. In addition, i.n. gliadin
displayed also small effect on preventing progression to clinical
diabetes in just prediabetic animals with advanced autoimmune
aggression within their islets. This prevention by an environmental
antigen - gliadin - is associated with local, mucosal induction of cd
T cells and to much lesser extent CD4+Foxp3+ T cells. Because
environmental factors play important roles in the recent increase
of T1D, environmental antigens related to T1D should be
considered for prevention trials. Our data suggest that intranasal,
mucosal vaccination with gliadin may represent a novel and
relatively safe approach to prevention and/or even early cure of
type 1 diabetes.
Acknowledgments
The authors would like to thank Helene Farlov of the Department of
Veterinary Disease Biology, Faculty of Health and Medical Sciences,
University of Copenhagen, for excellent technical assistance and help with
animal care.
Author Contributions
Conceived and designed the experiments: DPF PF KB. Performed the
experiments: DPF PF. Analyzed the data: DPF PF KB AKH. Contributed
reagents/materials/analysis tools: AKH KB DPF. Wrote the paper: DPF.
References
1. Onkamo P, Va¨a¨na¨nen S, Karvonen M, Tuomilehto J (1999) Worldwide increase
in incidence of Type I diabetes—the analysis of the data on published incidence
trends. Diabetologia 42:1395–1403.
2. Daaboul J, Schatz D (2003) Overview of prevention and intervention trials for
type 1 diabetes. Rev Endocr Metab Disord 4:317–323.
3. Homann D, Dyrberg T, Petersen J, Oldstone MB, von Herrath MG (1999)
Insulin in oral immune ‘‘tolerance’’: a one-amino acid change in the B chain
makes the difference. J Immunol 163:1833–1838.
4. Bergerot I, Fabien N, Maguer V, Thivolet C (1994) Oral administration of
human insulin to NOD mice generates CD4+ T cells that suppress adoptive
transfer of diabetes. J Autoimmun 7:655–663.
5. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K (1996) Aerosol
insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-
dependent diabetes. J Exp Med 184:2167–2174.
6. Ramiya VK, Shang XZ, Wasserfall CH, Maclaren NK (1997) Effect of oral and
intravenous insulin and glutamic acid decarboxylase in NOD mice. Autoim-
munity 26:139–151.
7. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, et al.
(1996) Nasal administration of glutamate decarboxylase (GAD65) peptides
induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp
Med 183:1561–1567.
8. Daniel D, Wegmann DR (1996) Intranasal administration of insulin peptide B:
9–23 protects NOD mice from diabetes. Ann N Y Acad Sci 778:371–372.
9. Chen W, Bergerot I, Elliott JF, Harrison LC, Abiru N, et al. (2001) Evidence
that a peptide spanning the B–C junction of proinsulin is an early Autoantigen
epitope in the pathogenesis of type 1 diabetes. J Immunol 167:4926–4935.
10. Atkinson MA (2011) Evaluating preclinical efficacy. Sci Transl Med 3:96cm22.
11. Herold KC, Bluestone JA (2011) Type 1 diabetes immunotherapy: is the glass
half empty or half full? Sci Transl Med 3:95fs1.
12. Hoorfar J, Buschard K, Dagnaes-Hansen F (1993) Prophylactic nutritional
modification of the incidence of diabetes in autoimmune non-obese diabetic
(NOD) mice. Br J Nutr 69:597–607.
13. Hoorfar J, Scott FW, Cloutier HE (1991) Dietary plant materials and
development of diabetes in the BB rat. J Nutr 121:908–916.
14. Scott FW (1996) Food-induced type 1 diabetes in the BB rat Diabetes Metab
Rev 12:341–359.
15. Funda DP, Kaas A, Bock T, Tlaskalova´-Hogenova´ H, Buschard K (1999)
Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev
15:323–327.
16. Schmid S, Koczwara K, Schwinghammer S, Lampasona V, Ziegler AG, et al.
(2004) Delayed exposure to wheat and barley proteins reduces diabetes
incidence in non-obese diabetic mice. Clin Immunol 111:108–118.
17. Cosnes J, Cellier C, Viola S, Colombel JF, Michaud L, et al. (2008) Incidence of
autoimmune diseases in celiac disease: protective effect of the gluten-free diet.
Clin Gastroenterol Hepatol 6:753–758.
18. Hansen D, Brock-Jacobsen B, Lund E, Bjørn C, Hansen LP, et al. (2006)
Clinical benefit of a gluten-free diet in type 1 diabetic children with screening-
detected celiac disease: a population-based screening study with 2 years’ follow-
up. Diabetes Care 29:2452–2456.
19. Klemetti P, Savilahti E, Ilonen J, Akerblom HK, Vaarala O (1998) T-cell
reactivity to wheat gluten in patients with insulin-dependent diabetes mellitus.
Scand J Immunol 47:48–53.
20. Norris JM, Barriga K, Klingensmith G, Hoffman M, Eisenbarth GS, et al.
(2003) Timing of initial cereal exposure in infancy and risk of islet autoimmunity.
JAMA 290:1713–1720.
21. Hansen AK, Ling F, Kaas A, Funda DP, Farlov H, et al. (2006) Diabetes
preventive gluten-free diet decreases the number of caecal bacteria in non-obese
diabetic mice. Diabetes Metab Res Rev 22:220–225.
22. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, et al.FELASA (Federation
of European Laboratory Animal Science Associations Working Group on
Health Monitoring of Rodent and Rabbit Colonies) (2002) Recommendations
for the health monitoring of rodent and rabbit colonies in breeding and
experimental units. Lab Anim 36:20–42.
23. Fousteri G, Chan JR, Zheng Y, Whiting C, Dave A, et al. (2010) Virtual
optimization of nasal insulin therapy predicts immunization frequency to be
crucial for diabetes protection. Diabetes 59:3148–3158.
24. Mestecky J (1987) The common mucosal immune system and current strategies
for induction of immune responses in external secretions. J Clin Immunol 7:265–
276.
25. Jaakkola I, Jalkanen S, Ha¨nninen A (2003) Diabetogenic T cells are primed both
in pancreatic and gut-associated lymph nodes in NOD mice. Eur J Immunol
33:3255–3264.
Intranasal Gliadin Prevents Type 1 Diabetes
PLOS ONE | www.plosone.org 9 April 2014 | Volume 9 | Issue 4 | e94530
26. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, et al. (2006) Anti-CD3
and nasal proinsulin combination therapy enhances remission from recent-onset
autoimmune diabetes by inducing Tregs. J Clin Invest 116:1371–1381.
27. Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, et al. (2006)
Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that
mediate antigen-specific transplantation tolerance. Diabetes 55:40–49.
28. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, et al. (2005) Defective
suppressor function in CD4(+)CD25(+) T-cells from patients with type 1
diabetes. Diabetes 54:92–99.
29. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA (2005)
Functional defects and the influence of age on the frequency of CD4+ CD25+ T-
cells in type 1 diabetes. Diabetes 54:1407–1414.
30. Lang FP, Schatz DA, Pollock BH, Riley WJ, Maclaren NK, et al. (1991)
Increased T lymphocytes bearing the gamma-delta T cell receptor in subjects at
high risk for insulin dependent diabetes. J Autoimmun 4:925–933.
31. Lang FP, Pollock BH, Riley WJ, Maclaren NK, Barrett DJ (1993) The temporal
association between gamma delta T cells and the natural history of insulin-
dependent diabetes. J Autoimmun 6:107–119.
32. Locke NR, Stankovic S, Funda DP, Harrison LC (2006) TCR gamma delta
intraepithelial lymphocytes are required for self-tolerance. J Immunol 176:6553–
6559.
33. Funda D, Stenvang JP, Buschard K (1995) Age-related changes in T gamma
delta cells of NOD mice. Immunol Lett 45:179–184.
34. Zhang L, Jin N, Nakayama M, O’Brien RL, Eisenbarth GS, et al. (2010)
Gamma delta T cell receptors confer autonomous responsiveness to the insulin-
peptide B:9–23. J Autoimmun 34:478–484.
35. Ke Y, Pearce K, Lake JP, Ziegler HK, Kapp JA (1997) Gamma delta T
lymphocytes regulate the induction and maintenance of oral tolerance.
J Immunol 158:3610–3618.
36. Diabetes Prevention Trial—Type 1 Diabetes Study Group (2002) Effects of
insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med
346:1685–1691.
37. Barker JM, McFann KK, Orban T (2007) Effect of oral insulin on insulin
autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study.
Diabetologia 50:1603–1606.
38. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, et al. (2011)
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in
patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Lancet 378:319–327.
39. Hanninen A, Harrison LC (2004) Mucosal tolerance to prevent type 1 diabetes:
can the outcome be improved in humans? Rev Diabet Stud 1:113–121.
40. Rose NR, Bona C (1993) Defining criteria for autoimmune diseases (Witebsky’s
postulates revisited). Immunol Today 14:426–430.
41. Chatenoud L, Bach JF (2005) Regulatory T cells in the control of autoimmune
diabetes: the case of the NOD mouse. Int Rev Immunol 24:247–267.
42. Ha¨nninen A, Braakhuis A, Heath WR, Harrison LC (2001) Mucosal antigen
primes diabetogenic cytotoxic T-lymphocytes regardless of dose or delivery
route. Diabetes 50:771–775.
43. Fousteri G, von Herrath M, Bresson D (2007) Mucosal exposure to antigen:
cause or cure of type 1 diabetes? Curr Diab Rep 7:91–98.
44. Strobel S, Mowat AM (1998) Immune responses to dietary antigens: oral
tolerance. Immunology Today 19:173–181.
45. Palova-Jelinkova L, Rozkova D, Pecharova B, Bartova J, Sediva A, et al. (2005)
Gliadin fragments induce phenotypic and functional maturation of human
dendritic cells. J Immunol 175:7038–7045.
46. Thomas KE, Sapone A, Fasano A, Vogel SN (2006) Gliadin stimulation of
murine macrophage inflammatory gene expression and intestinal permeability
are MyD88–dependent: the role of the innate immune response in celiac disease.
J Immunol 176:7512–2521.
47. Nikulina M, Habich C, Flohe SB, Scott FW, Kolb H (2004) Wheat gluten causes
dendritic cell maturation and chemokine secretion. J Immunol 173:1925–1933.
48. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, et al. (2003) Association
between innate response to gliadin and activation of pathogenic T cells in coeliac
disease. Lancet 5:30–37.
49. Funda DP, Kaas A, Tlaskalova´-Hogenova´ H, Buschard K (2008) Gluten-free
but also gluten-enriched (gluten+) diet prevent diabetes in NOD mice; the gluten
enigma in type 1 diabetes. Diabetes Metab Res Rev 24:59–63.
50. Galipeau HJ, Rulli NE, Jury J, Huang X, Araya R, et al. (2011) Sensitization to
gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8
mice. J Immunol 187:4338–4346.
51. Antvorskov JC, Fundova P, Buschard K, Funda DP (2012) Impact of dietary
gluten on regulatory T cells and Th17 cells in BALB/c mice. PLoS ONE
7:e33315.
Intranasal Gliadin Prevents Type 1 Diabetes
PLOS ONE | www.plosone.org 10 April 2014 | Volume 9 | Issue 4 | e94530
